Aficamten

10 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyAficamtenexercise capacity

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial

By MedXY|Jun 28, 2026

The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

Aficamten

Latest news

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM

Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy

VO2T12.5% Emerges as a Key Physiological Marker for Cardiac Performance and Treatment Efficacy in Obstructive HCM

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

Aficamten: A Breakthrough Oral Therapy for Obstructive Hypertrophic Cardiomyopathy Across Symptom Severity

Aficamten in Obstructive Hypertrophic Cardiomyopathy: Durable 48-Week Benefits and Insights on Combination Therapy